#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Oesophageal achalasia Infertility female Autoimmune demyelinating disease HER2 mutant non-small cell lung cancer Renal transplant Vascular malformation Neuroendocrine cell hyperplasia of infancy Thrombocytopenia Aspergillus infection Mantle cell lymphoma recurrent Becker's muscular dystrophy Anal fistula Multiple system atrophy Stress cardiomyopathy Urethral valves More trials…

    Learn about Rare Diseases

    Familial haemophagocytic lymphohistiocytosis – Trials in Disease Alexander disease – Basic Information Familial haemophagocytic lymphohistiocytosis – Diagnostics Lymphangioma Biotinidase deficiency Breast angiosarcoma – Trials in Disease Angiosarcoma recurrent – Diagnostics Hereditary motor and sensory neuropathy – Treatment Hereditary motor and sensory neuropathy – Basic Information Noonan syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Nicotine Resinate Mirikizumab Quinapril Hydrochloride Zasocitinib Cefixime Trihydrate NIZUBAGLUSTAT Sparsentan Apl-101 Gedatolisib Pioglitazone Hydrochloride SAR445399 ENSIFENTRINE Deupirfenidone Guselkumab Bi 1015550 Etrumadenant Protrans TX000045 Irbesartan Ptg-Carcik-Cd19 More therapies…

    Learn about Your Condition

    Kearns-Sayre syndrome Pruritus Pneumococcal infection Small cell lung cancer Brain abscess Immunosuppression HER2 positive breast cancer Haemorrhage intracranial Infertility Multifocal motor neuropathy Cardiac failure congestive Rhabdoid tumour Behavioural addiction Nephroblastoma Glomerulonephritis acute More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie…

Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie

Ul. Jagiellonska Nr 78, Olsztyn, 10-357, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study of V940 and Pembrolizumab for Patients with Resected Stage II, IIIA, IIIB Non-Small Cell Lung Cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Mrna-4157
    • Pembrolizumab
    Belgium Czechia Denmark Estonia Finland France +12

  • Study on the Safety and Effects of Divarasib with Pembrolizumab and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Divarasib
    • Budesonide
    • Carboplatin
    Belgium Italy The Netherlands Poland Spain Sweden

  • Study on Long-term Safety of Nivolumab and Drug Combination for Cancer Patients from Previous BMS Trials

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Disodium Folinate
    • Trametinib
    • Rucaparib
    Austria Belgium Czechia France Germany Greece +4

  • Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Datopotamab Deruxtecan
    • Infliximab
    • Mycophenolate Mofetil
    Austria Belgium Germany Hungary Italy Poland +1

  • Study on THIO and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage III
    • Non-small cell lung cancer
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • 2-Amino-9-((2R,4R,5R)-4-Hydroxy-5-(Hydroxymethyl) Tetrahydrofuran-2-Yl)-1,4,5,9-Tetrahydro-6H-Purine-6-Thione
    • Cemiplimab
    Bulgaria Hungary Poland Romania

  • Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Favezelimab
    • Olaparib
    • Lenvatinib
    Austria Belgium Czechia Denmark Estonia Finland +15

  • Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • K-ras gene mutation
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Divarasib
    • Budesonide
    • Carboplatin
    Belgium Denmark France Germany Greece Hungary +6

  • Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Adagrasib
    • Pembrolizumab
    Austria Belgium Bulgaria Croatia Czechia Denmark +13

  • Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Telisotuzumab Vedotin
    • Docetaxel
    Austria Belgium Bulgaria Czechia Denmark France +10

  • Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    • ADMILPARANT
    Austria Belgium Denmark Finland France Germany +8
Previous Page
1 2 3 4 5 … 8
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!